Posted by AGORACOM-JC
at 10:24 AM on Wednesday, August 21st, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE)
Sustainable low cost, high quality cannabinoid production and
procurement focusing on both bio-pharmaceutical development and
Cannabinoid Infused Products. Learn More.
NBUD: CSE
CBD usage in beverages; functionality, cultural acceptance and legislation
growth of the legal cannabis industry has opened doors to new product innovations, particularly in beverages, with no signs of slowing down.
According to Zenith Global, the CAGR forecast for 2018- 2023 volume sales is 75%, with 5.2 million litres of CBD drinks consumed in the US in 2018.Â
The growth of the legal cannabis industry has opened doors to new product innovations, particularly in beverages, with no signs of slowing down. According to Zenith Global, the CAGR forecast for 2018- 2023 volume sales is 75%, with 5.2 million litres of CBD drinks consumed in the US in 2018.Â
Although CBD is being included in alcoholic drinks such as low ABV beer,
with a trending decline in alcohol consumption, new CBD categories such
as RTD coffee, sodas and water-based drinks are posed to be a high
growth market for the beverage sector.
The culture of cannabis is evolving
from a product associated with negative, psychoactive effects to being
full of medically-backed health benefits previously unexplored and
underappreciated.
To better understand why the CBD use
in beverages is enjoying a recent boom, we should examine where it comes
from and how the body utilises it.
Defining Cannabis, CBD, THC, marijuana and hemp
Cannabis – or more the more biologically correct Cannabis Sativa – is the umbrella term for both marijuana and hemp.
They are of the same genus and species with the main divertive being
the THC content of each. They look nearly identical, with marijuana
being illegal and hemp being legal. There are many strands of Cannabis,
however we will touch base on just the two mentioned, which contain both
the cannabinoids (plant oils) THC and CBD in different concentrations.
Cannabis makes most of its cannabinoids in its flowers, which are more
commonly referred to as “budsâ€.
Marijuana
tends to contain high levels of THC and lower levels of CBD and
requires certain sometimes controlled conditions to grow fruitfully. It
also has a higher concentration of cannabinoids per gram so generates a
better yield. Hemp
will contain higher levels of CBD and trace amounts of THC with a lower
yield of cannabinoids, so it tends to take more plants to extract the
same amount of CBD.
Difference between CBD and THC and how they function in the body
Since research on cannabis is still
fresh as it was only partially legalised recently, most of its
functionality is yet unknown. Cannabis is theorised to work like many
other drugs, binding to receptors in our body.
Interestingly, our bodies are set up
to accept cannabinoids already. The endocannabinoid system (ECS) is a
complex cell-signalling system in the body that we so far understand to
play a role in regulating a range of functions in the body such as
sleep, mood and memory, according to an article by Healthline.com.
The ECS actively exists in our body
and we already naturally produce endocannabinoids, even if we do not
consume cannabis. A similar comparison of a process in the body that
does a similar process would be the pancreas produce insulin for our
blood sugar regulation.
So not only do we produce our own
endocannabinoids, we have two main receptors that accept them; CB1
receptors mainly found central nervous system and CB2 receptors found
mainly in the peripheral nervous system. Once bound to either of these
receptors, the endocannabinoids can then tell the ECS system the action
needs to happen i.e., boost our mood, relieve pain or go to sleep.
Once our endocannabinoids have served
their purpose, they must be broken down by enzymes in the body, which
are regularly regenerating.
It appears the main function of the
endocannabinoid system is to maintain bodily homeostasis, states a
report by the Facultad de Medicina at University of Buenos Aires.
So now that we defined the difference
between THC and CBD, what do they actually do when they are in the
body? Since we know that the ECS receptors are linked with the nervous
system, it’s understandable that the sides effects we hear about
cannabis tend to be related to relaxation.
THC –
tetrahydrocannabinol- the compound which can get you ‘high’, binds to
the CB1 and CB2 receptors just like our bodily endocannabinoids, almost
like a substitute.
THC can have positive effects such as
stimulating appetite, which can be great for medical patients who find
it difficult to eat, but it is also responsible for side effects such as
paranoia. THC is more frequently used for therapy since is similarity
to our own endocannabinoids is nearly identical. Currently there is not a
way to separate the two effectively, but research is continuing.
CBD – cannabidiol–
which typically doesn’t have any negative effects, would be seen to be
the superior compound and used more widely. So why bother using THC if
CBD is better and easier to regulate? CBD actually works best in
conjunction with THC, because CBD doesn’t appear to interact with our
ECS the way THC does by binding to receptors.
Though experts aren’t quite sure,
it’s believed that CBD may work by preventing our endocannabinoids from
being broken down and allowing them to have a longer effect on the
body.
As CBD is more widely accepted and
there are less legal restrictions on this compound currently, it is
being more readily used in beverages as opposed to THC.
Cultural acceptance and legalisation worldwide
Regulation is ongoing, and constantly
changing worldwide. As of press time, CBD is legal in all 50 of the US,
as long as it contains less than 0.3 % of THC, though some states
require you to have a prescription to purchase it, such as Virginia.
THC is legal in 10 states with a
prescription, and in an additional 23 states with a doctor’s
prescription. The US Food and Drug administration has approved four
cannabis related drug products, however they are only available with a
prescription from a licenced healthcare provider.
Press and recent legalisation,
particularly in the US, has brought CBD to the public’s attention while
increasing demand for new, innovative ways to consume it. For those
unfamiliar with the drug but curious to try it, beverages are seemingly
the most accessible (and perhaps culturally acceptable) way to consume
the cannabis-based product. The category is still in early stages, with
fragmented legislation fuelling conflicting information from multiple
sources about usage, benefits and dosages.
The most popular way to consume CBD
it is through oil, as CBD is naturally soluble and most effective
delivered in fat. It is also easy to control dosages this way which is
handy for consumers. This easy-to-consume format comes in dropper
applications called tinctures. Though with the rise in innovation
through beverages and food, this could change in the next few years.
CBD is now popping up in snacks and even ice cream
with doses ranging per serving of 10-50mg. As CBD is still very new to
the market there aren’t many regulations on quantities in food and
beverage due to its minimal side effects, though the expense of the
ingredient will affect the price point of the product. It’s always best
to check the label and research the effects of CBD before consumption.
Posted by AGORACOM-JC
at 9:21 AM on Wednesday, August 14th, 2019
Announced the completion of its 24,500 square foot phase one indoor cannabis cultivation facility located on 135 acres of land in Low, Quebec, Canada.
This week consultants are finalizing the facility’s Evidence of Readiness Package for submission to Health Canada.
“This is an important milestone for NORTHBUD, as we transition from the construction phase to pre-operational phase,†said Ryan Brown, CEO of NORTHBUD.
TORONTO, Aug. 14, 2019 — North Bud Farms Inc.(CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce the completion of its 24,500 square foot phase one indoor cannabis cultivation facility located on 135 acres of land in Low, Quebec, Canada. This week consultants are finalizing the facility’s Evidence of Readiness Package for submission to Health Canada.
“This is an important milestone for NORTHBUD, as we transition from
the construction phase to pre-operational phase,†said Ryan Brown, CEO
of NORTHBUD. “We believe that we have built an extremely cost-effective
facility that will allow us to be competitive in all aspects of the
Canadian market. With the addition of over 500,000 square feet of
outdoor production later this year, we anticipate production of over 10
million grams of Cannabis in calendar 2020.â€
Creation of New U.S. Subsidiary
NORTHBUD wishes to inform shareholders that they have established a
wholly owned U.S. based subsidiary. Bonfire Brands USA Inc. has been
established to own and operate NORTHBUD’s proposed acquisitions in the
U.S. markets.
NORTHBUD is pleased to announce that it has appointed Justin Braune
as President of Bonfire Brands USA. Mr. Braune currently serves as the
CEO of EUREKA Vapor and will lead all of the NORTHBUD’s U.S. operations.
Mr. Braune brings over 10 years of industry experience to the
NORTHBUD team. A graduate of the United States Naval Academy, he served
in the U.S. Navy for ten years where he helped manage nuclear reactor
systems aboard the USS Ronald Reagan. He holds an MBA from the
University of Southern California’s Marshall School of Business.
Prior to joining EUREKA Vapor, Mr. Braune served as President at Made
By Science, a startup science and delivery technology company which was
recently acquired by Acreage Holdings. Mr. Braune has served as CEO and
President for multiple startup private and public companies over his
10-year career in the cannabis industry.
“I look forward to working with Justin as we move into the
operational phase of our U.S. expansion plan,†said Ryan Brown, CEO of
NORTHBUD. “Justin has extensive contacts in the U.S. cannabis industry
which will be very valuable as we continue to expand and enter into new
partnerships.â€
About North Bud Farms Inc. North Bud Farms Inc.,
through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a
licence under The Cannabis Act. The Company has built a state-of-the-art
purpose-built cannabis production facility located on 95 acres of
Agricultural Land in Low, Quebec, Canada. North Bud Farms Inc. has
entered into agreements to acquire assets in California, Colorado and
Nevada.
Neither the Canadian Securities Exchange (the “CSEâ€) nor its
Regulation Services Provider (as that term is defined in the policies of
the CSE) accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements Certain statements and
information included in this press release that, to the extent they are
not historical fact, constitute forward-looking information or
statements (collectively, “forward-looking statementsâ€) within the
meaning of applicable securities legislation. Forward-looking
statements, including those identified by the expressions “anticipateâ€,
“believeâ€, “planâ€, “estimateâ€, “expectâ€, “intendâ€, “mayâ€, “should†and
similar expressions to the extent they relate to the Company or its
management. Forward-looking statements are based on the reasonable
assumptions, estimates, analysis and opinions of management made in
light of its experience and its perception of trends, current conditions
and expected developments, as well as other factors that management
believes to be relevant and reasonable in the circumstances at the date
that such statements are made, but which may prove to be incorrect.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the Company to differ materially from any
future results, performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among
others, the risk factors included in the Company’s final long form
prospectus dated August 21, 2018, which is available under the Company’s
SEDAR profile at www.sedar.com.
Accordingly, readers should not place undue reliance on any such
forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which such statement is made. New factors
emerge from time to time, and it is not possible for the Company’s
management to predict all of such factors and to assess in advance the
impact of each such factor on the Company’s business or the extent to
which any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. The Company does not undertake any obligation to update any
forward-looking statements to reflect information, events, results,
circumstances or otherwise after the date hereof or to reflect the
occurrence of unanticipated events, except as required by law including
securities laws. This news release does not constitute an offer to sell
or a solicitation of any offer to buy any securities of the Company.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT: North Bud Farms Inc. Edward Miller VP, IR & Communications Office: (855) 628-3420 ext. 3 [email protected]
Tags: Cannabis, CBD, CSE, Hemp, Marijuana, otc, stocks, tsx, tsx-v, weed Posted in North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Completes Construction of its Phase One Cultivation Facility and Establishes U.S. Based Subsidiary, Bonfire Brands USA $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 11:09 AM on Wednesday, August 7th, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.
NBUD: CSE
Drink Makers Seek to Include CBD and Cannabis Beverage Alternatives
According to data compiled by Fior Markets, the global cannabis beverages market is expected to reach USD 4.56 Billion by 2025 while exhibiting a CAGR of 16.8% during the forecast period from 2018 to 2025.
In particular, edibles are more abundant in regions where recreational cannabis is legal. On the other hand, the cannabis-infused beverage industry is experiencing significant strength because of large beverage corporations entering into the marketspace.
NEW YORK, Aug. 7, 2019 — As the cannabis industry continues to develop, savvy consumers and businesses are creating innovative new ways to ingest cannabis. Due to widespread stereotypes, many imagine cannabis users relying on hastily rolled joints. However, as the legal industry continues to accelerate, new products are constantly emerging. For instance, in legal markets such as Colorado or California, extracts and concentrates have become increasingly popular because of their potency and immediate effects. Specifically, Colorado has witnessed its extract and concentrate sales eclipse its flower sales in recent years. And while extracts and concentrates are widely popular, other vendors have incorporated cannabis into edibles and beverages.
In particular, edibles are more abundant in regions where
recreational cannabis is legal. On the other hand, the cannabis-infused
beverage industry is experiencing significant strength because of large
beverage corporations entering into the marketspace. Notably, big
alcohol has set its sights on the cannabis market because of its
declining primary revenue drivers. As a result, many companies are
adding cannabis-infused beverages to their product lines in order to
combat lower sales numbers that are a result of the declining alcohol
consumption levels. However, to note, most companies are predominantly
only adding CBD, or cannabidiol, to their beverages because of
regulatory restrictions on THC.
Moreover, companies are marketing CBD-infused beverages as health and
wellness products rather than recreational or relaxation products. And
while the infused beverage market is already experiencing a surge in
momentum in legal regions, it’s expansion into new territories is
expected to spur its growth. According to data compiled by Fior Markets,
the global cannabis beverages market is expected to reach USD 4.56 Billion by 2025 while exhibiting a CAGR of 16.8% during the forecast period from 2018 to 2025.
Tags: Cannabis, CBD, CSE, Hemp, Marijuana, otc, stocks, tsx, tsx-v, weed Posted in North Bud Farms Inc | Comments Off on North Bud Farms Inc. $NBUD.ca – Drink Makers Seek to Include #CBD and #Cannabis Beverage Alternatives $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 3:29 PM on Monday, July 29th, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.
NBUD: CSE
Beverage Companies Look to Capitalize on CBD’s Benefits and Accessibility
According to data compiled by Hemp Business Journal, a division of New Frontier Data, sales for the U.S. hemp industry totaled USD 820 Million in 2017.
Research suggests that the industry is expected to grow to USD 1.9 Billion by 2022 at a CAGR of 14.4% during the 5-year period.
NEW YORK, July 26, 2019 – For centuries, hemp has been used for a vast array of applications. In particular, hemp was predominantly used to manufacture textiles, paper, and construction materials because of its durability. However, now hemp has become even more popular because of its CBD compound. Hemp is derived from the cannabis plant and is one of the two main families found within the plant, the other being marijuana. Unlike marijuana, hemp’s main active component is CBD or cannabidiol, which does not cause psychoactive effects for its consumer.
Generally, the hemp plant contains less than 0.3% THC levels, which
is an insignificant amount. However, because hemp is derived from the
cannabis plant, federal regulators deemed hemp to be unsafe, and as a
result, hemp and its CBD compound were listed as a controlled substance.
Yet, researchers and scientists have begun new studies to better
understand the biological makeup of hemp and compiled compelling results
that went against the previously established understanding of the plant
and its effects. As a result of these studies and the non-psychoactive
nature of hemp, regulators lowered the scheduling of hemp and its CBD
compound on the controlled substance list.
Moreover, the passage of the U.S. Farm Bill paved the way for the
broader CBD industry, further accelerating its presence in legal
channels. Previously, the U.S. Department of Agriculture and other state
departments only allowed pilot programs to study hemp, which allowed
for small-scale cultivation. To note, the Farm Bill legalized the
commercialization hemp and CBD, which caused a spur of retailers to add
the product to their shelves. For instance, local stores and even
e-commerce giants have CBD-based products being publicly sold for
every-day consumers. Notably, the bill does not put any restrictions on
the sale, transport, or possession of hemp-derived products, meaning
that CBD is federally legal as long as it is consistent with the law.
Now, the CBD market is one of the fastest-growing market segments
within the cannabis industry, due in large part to its lenient
guidelines. And as a result, more companies are looking to enter into or
expand within the CBD marketplace because of the vast potential that
has opened up for the market. According to data compiled by Hemp
Business Journal, a division of New Frontier Data, sales for the U.S.
hemp industry totaled USD 820 Million in 2017. The research suggests that the industry is expected to grow to USD 1.9 Billion by 2022 at a CAGR of 14.4% during the 5-year period.
In 2017, hemp-derived CBD products accounted for the largest market share, as the segment delivered sales of USD 190 Million,
accounting for 23% of the overall market share that year. Other
segments such as personal care, food, and industrial care followed
closely. However, by 2022, CBD products are expected to take off,
outpacing the rest of the hemp sector. Hemp-derived CBD products are
anticipated to deliver sales of USD 646 Million by 2022, followed by industrial application sales of USD 527 Million.
While other segments are projected to grow, they are nonetheless
expected to lag behind the exponential growth of the CBD product
segment. CBD can be used to simply relax after a strenuous and stressful
day but it is now being leveraged within the medical sector for
patients suffering from ailments such as arthritis, multiple sclerosis,
chronic pain, and epilepsy.
In particular, the U.S. Food and Drug Administration has already
legalized a CBD-based drug, Epidiolex, which is used to treat epilepsy.
However, the FDA has mentioned that researchers will need to conduct
more large-scale positive clinical trials in order for cannabis-based
treatments to be approved. Currently, evidence of CBD effects comes from
animal testing or very small-scale clinical trials that are minuscule
compared to the FDA’s standards. For example, Esther Blessing, a psychiatrist and researcher at New York University,
pointed to a 2011 study where a few dozen people who had anxiety
disorders were asked to speak in front of a large audience. The study
concluded that people who received CBD reported significantly less
anxiety compared to those who received the placebo.
Posted by AGORACOM-JC
at 11:41 AM on Monday, July 22nd, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.
Welcome to the Cannabis Countdown.
In this week’s rendition, we’ll recap and countdown the top 10
marijuana industry news stories for the week of July 15th – 21st, 2019.
With Thailand’s legalization of medical cannabis in February, some
experts predict that other Southeast Asian countries may move to
decriminalize the plant. If that happens, it could prove a significant
opportunity for investors interested in the space.
At the end of 2018, Canada, the United States, and Mexico agreed on
new terms to replace the North American Free Trade Agreement (NAFTA).
The new treaty, the Canada-United States-Mexico Agreement (CUSMA),
establishes updated legal language surrounding trade tariffs,
environmental and labour regulations, and intellectual property
protections.
It was only just last year that Canopy GrowthCGC 2.14% completed
the first legal export of medical cannabis to the United States. As the
world waits for the United States and Canada to follow Mexico in
ratifying the new trade agreement, this is what cannabis investors
should know about how the deal affects the marijuana industry.
Hip-hop star A$AP Rocky made global headlines in July because of an
altercation and is now locked up Sweden. Thousands of fans and even
politicians like President Trump are calling for his release.
Like many other rappers, A$AP Rocky’s fortunes are not tied up only
in lyrics. These famous artists aren’t just signing record deals
anymore. Top rappers are now signing lucrative weed contracts.
Now that cannabis is going mainstream, let’s take a look at the top ten hip hop artists who are capitalizing on the green rush.
U.S. health authorities are taking final comments from the public on
how to regulate over-the-counter cannabis extracts such as CBD. The
suggestions are due to the U.S. Food and Drug Administration (FDA) by
midnight ET Tuesday, July 16, on how the agency should regulate
cannabis-derived products.
The FDA has vowed to expedite its review of cannabis-derived
compounds because of a surge in CBD products hitting the market. The
agency now says it will have an update on the review by late summer or
early fall.
The Ohio House on Wednesday voted 88-3 in favor of legislation that
would move Ohio closer to decriminalizing hemp and hemp products,
including CBD oil. Under current state law, hemp is considered a
Schedule I drug because it — like marijuana — comes from the cannabis
plant. However, hemp contains a low concentration of THC, marijuana’s
psychoactive stimulant.
The bill would exclude hemp and its products from the definition of
marijuana that the state uses to enforce controlled substance laws, and
it would further prohibit the state’s Board of Pharmacy from listing
hemp as a controlled substance.
But the award may come at a cost for Aurora as the average price it
offered – 1.73 euros per gram ($1.94) – was less than half the tender
reference prices and only slightly above the company’s latest reported
average “cash cost of sales per gram of dried cannabis sold.â€
On June 15, Fenwick resident Nick Lalonde, who worked at the Balfour
Street site for almost two years, had emailed the Voice and several
Health Canada employees with various allegations of infractions—
including cannabis being grown in unlicensed areas.
If you weren’t already convinced that cannabis has gone mainstream — you will be now.
American rapper, business mogul, and all-around cultural giant, Shawn
“Jay-Z†Carter, just announced a multi-year partnership with this
leading California cannabis company. In addition to helping strengthen
the company’s bottom line, Jay-Z will also look to create opportunities
for those hurt by the prohibition of cannabis.
When it comes to bringing cannabis banking out of the informal cash
exchange world and into America’s banking sector with Senate’s support,
the train is finally leaving the station. The Senate has scheduled a
hearing next week to discuss cannabis companies and their access to
legitimate banking.
Open and fair banking access for cannabis companies in the United
States will play a crucial role in the industry’s expansion and will
eventually lead to the implementation of interstate and online cannabis
commerce.
Posted by AGORACOM-JC
at 11:28 AM on Thursday, July 18th, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.
NBUD: CSE
—————
Booming Demand for CBD Is Making Hemp the Cannabis Cash Crop
Players in the $340 billion global cannabis market are turning their attention to weed’s less-regulated cousin, hemp.
Hemp is a strain of cannabis whose fibers have traditionally been used in textiles and rope, and farmers can grow it even in countries with strict drug laws because it has different properties from marijuana.
By Craig Giammona and Bruce Einhorn
Mention legal cannabis, and many people think of the weed stores that have sprung up in Boston, Denver, Seattle, and other major U.S. cities.
Inside, infused brownies and vape pens are sold next to branded joints
and neatly packaged bags of marijuana presented in a way that wouldn’t
be out of place in any American mall. In Canada you can even order pot
through the mail, and some of the world’s alcohol giants have set up
shop there to develop weed beer.
But the business of getting people high is only part of the cannabis
craze. Marijuana is still banned for recreational use across much of the
world, and even medical access, while expanding, is restricted in most
countries. So players in the $340 billion global cannabis market are
turning their attention to weed’s less-regulated cousin, hemp.
Marijuana 101
• THC: Tetrahydrocannabinol is the chemical in marijuana that produces a high. • CBD: Cannabidiol, a nonintoxicating compound, can be derived from hemp and marijuana. •
Cannabis: Hemp and marijuana are both types of cannabis. Hemp faces
fewer restrictions because it’s generally cultivated with lower levels
of THC.
Hemp is a strain of cannabis whose fibers have traditionally been
used in textiles and rope, and farmers can grow it even in countries
with strict drug laws because it has different properties from
marijuana. Most important to law enforcement officials, it’s low in THC,
the compound that gets you stoned. But businesses are buzzed about its
other defining characteristic: a higher concentration of cannibidiol, or
CBD, a nonpsychoactive chemical at the center of a wellness trend sweeping the U.S. and expanding worldwide.
Global Market Share and Sales by Hemp Product Category in 2018
Data: Hemp Business Journal
CBD is being pitched as an all-natural way to alleviate ailments
including pain, inflammation, anxiety, and insomnia. Despite a paucity
of science to back up such claims, CBD has become a coveted ingredient
in a host of consumer products, from skin lotions to sparkling water to
tinctures to dog biscuits.
The surge in demand is fueling a global Green Rush, even in countries
where a legal market for cannabis products was unthinkable just a few
years ago. “We are getting phone calls from big pharma groups in Asia,
all parts of the world: ‘Can you get product? Can you supply to us?’ â€
says Glenn Davies, chief executive officer of industrial hemp grower
CannAcubed Pte. The Singapore-based startup planted its first commercial
hemp crop in May in China’s Yunnan province. “It’s all about hemp.â€
One of the first plants ever domesticated, cannabis was used for
thousands of years for fiber, food, and medicine. Yet for the better
part of the last century it’s largely been traded on the black market,
banned in many countries alongside cocaine, heroin, and other controlled
substances. Much of that bad-boy reputation faded last year when Congress legalized CBD in the U.S.
Researchers estimate the market for CBD in the U.S. alone could be
worth almost $24 billion by 2023. In Canada sales of legal cannabis may
reach $4.7 billion by that time, up from about $570 million last year,
according to BDS Analytics. Annual sales of CBD could potentially be
larger than those of marijuana, analysts say, because of the large
number of products in which it can be used.
U.S. Hemp Imports by Source Region, 2017
Data: Hemp Business Journal
Investors are pouring money into massive CBD extraction facilities
and processing plants in the U.S., hoping to be ready when Coca-Cola
Co., Procter & Gamble Co., and other consumer giants finally embrace
cannabis. Colorado CBD company Mile High Labs
has developed technology to remove unrefined hemp extract from the
plant, and it recently paid $18.8 million for a 400,000-square-foot
former Novartis factory where it will make products such as lotions and
tinctures.
American farmers are plowing into the hemp industry in Colorado,
Kentucky, Montana, Oregon, and other states. This year, more than
200,000 acres of hemp are licensed to be planted in the U.S., up from
roughly 25,000 two years ago. Asia, which has a long history with
natural medicines, is also seeing growing interest in cannabis. In 2017,
China planted at least 113,000 acres of hemp, according to New
Frontier, an industry researcher. Cultivation is also on the rise in
Colombia, Greece, Jamaica, and even the southern African nation of
Lesotho. “You get the domino effect: The farmer in Bulgaria looking
across at peers in Greece and asking questions, putting pressure on the
government to make similar steps,†says Shane MacGuill, an analyst at
Euromonitor International. “The more it happens, the more quickly we get
the spread of cultivation.â€
Hemp producers in Asia and other lower-cost regions could
ultimately undercut U.S. farmers, especially as the quality of their
crop improves and a global market takes shape, with hemp moving freely
across borders like any other agricultural commodity. In June,
CannAcubed leased two factories in Yunnan, one of only three Chinese
provinces that allows the production of hemp; it plans to expand them
into CBD research and extraction facilities.
Not everyone is so sanguine. Mark Mees, CEO of Setek Therapeutics in
New Zealand, sees cannabis becoming another agricultural commodity, with
prices racing downward. And Mees, whose company has a license to grow
medical marijuana in the country, says the CBD business has been
overhyped. “You get a few hippies and that’s great. One thing that’s
missing is old-fashioned business sense,†he says. “We will see a train
wreck of small companies that completely underestimated the costs and
the complexity of what they’re trying to do.â€
Global Hemp Sales
Data: Hemp Business Journal
Restrictions on medical pot are loosening globally. More than 50
countries, including Australia, Brazil, and Germany, have legalized
access to medicinal cannabis, according to Bloomberg Intelligence,
making it easier for farmers to plant hemp or marijuana. But dealing
with pot can still be tricky. In New Zealand, companies can grow medical
weed only for research, though the government is working on a
commercialization plan. Cannasouth Ltd. has struggled as New Zealand’s sole publicly traded cannabis company, with its shares falling 24% since its IPO on June 19.
As countries remove restrictions, cannabis prices could fall. That
would hurt farmers, but potentially boost the profit margins of
companies using cannabis as an ingredient. Worries about an industry
bubble surfaced earlier this year in China after investors flocked to
companies linked to cannabis. Regulators sought to rein in the
enthusiasm, with the Shenzhen Stock Exchange telling companies to warn
investors about uncertainties facing their industrial cannabis projects.
Canadian farmers have seen a hemp boom-and-bust cycle before. The
crop was legalized for production in 1998, and farmers benefited when
hemp seed took off as a health-food product. Business peaked in 2015 as
South Korean demand drove the market. But China, becoming a cheaper
supplier for Korean buyers, sucked profit away from Canada’s hemp-seed
farmers. Still, that hasn’t deterred Canadians from trying to cash in on
CBD. This year, hemp acreage in the country is expected to more than
double, to about 82,000 acres.
In Asia, CannAcubed’s Davies is also unfazed by the risks. “Everybody is trying to have the same outcome and objective: Get this industry moving,†he says. —With Ashley Robinson BOTTOM LINE – Fueled by growing demand for CBD as a health-enhancing ingredient in foods and beauty products, sales of the cannabis derivative could hit $24 billion in the U.S. by 2023.
Tags: Cannabis, CBD, CSE, Hemp, Marijuana, otc, stocks, tsx, tsx-v, weed Posted in North Bud Farms Inc | Comments Off on North Bud Farms Inc. $NBUD.ca – Booming Demand for #CBD Is Making Hemp the #Cannabis Cash Crop $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 5:22 PM on Monday, July 15th, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.
NBUD: CSE
—————
The Week In Cannabis: Jay-Z Joins Caliva, Congress Holds Marijuana Hearings, CannTrust Gets Smoked, And More
“Jay-Z entering the cannabis space reaffirms that effective brands will drive the future of the cannabis industry.
We applaud his efforts to be a part of the solution in righting the disproportionate impact that the war on drugs has had on minority communities. Jay personifies the perfect mix of celebrity, entrepreneur and true brand,” said Kraig Fox, CEO of High Times, which first reported the news.Â
On the policy front, Hawaii decriminalized the possession of small
amounts of marijuana, and the U.S. Congress held a landmark hearing
regarding cannabis legalization and the need to reform. Here’s what legalization advocates had to say. In addition, the FDA said
it was “expediting its work to address the many questions about
cannabidiol (CBD),†and Rep. Alexandria Ocasio-Cortez (D-NY) and Sen.
Kamala Harris (D-CA) introduced bills in Congress that seek to ensure
that people with low-level drug convictions are still able to access
public housing, reported Kyle Jaeger on Marijuana Moment.
We also saw a new ETF debut on the NYSE this week. The Cannabis ETF (NYSE: THCX) launched by Innovation Shares claims to be the only pure-play cannabis ETF, with no exposure to tobacco or alcohol.
The fund has lower fees than its NYSE peers and differentiates
itself from others on the back of its monthly rebalancing strategy,
versus a more standard quarterly rebalancing approach, fund adviser Jon
Najarian told Benzinga.
CannTrust Holdings Inc (NYSE: CTST)
got smoked after Health Canada discovered one of its facilities was
non-compliant with regulations. Later in the week, it was reported that
illicitly produced cannabis had been not only sold in Canada but also
exported to Denmark.
“420 Investor” Alan Brochstein told Benzinga he thinks CEO Peter
Aceto should apologize for violating Health Canada rules and resign.
Debra Borchardt, CEO of Green Market Report, said the CannTrust
scandal shows that public cannabis companies can’t always be trusted to
do the right thing.
“This company grew plants in an unlicensed room and figured they’d
get away with it, which is a sign of incredibly poor judgment since this
is such a highly regulated industry. They also admitted to storage
problems at another facility and have since stopped sales,” she said.
The poor decision-making by company leaders hurts patients and shareholders alike, Borchardt said.
“Hiring a quality control officer after the fact just shows this company did too little too late.â€
We invite you to check out our story of the week: “From Coffee To
Cannabis: Colombian Legislators To Move For Adult-Use Legalization.”
Tags: Cannabis, CBD, CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in All Recent Posts, North Bud Farms Inc | Comments Off on North Bud Farms Inc. $NBUD.ca – The Week In Cannabis: #Jay-Z Joins #Caliva, #Congress Holds #Marijuana Hearings, #CannTrust Gets Smoked, And More $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 12:35 PM on Tuesday, July 9th, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.
NBUD: CSE
—————
Consumer Entry into the Cannabis Market Spikes Post Legalization
Global marijuana market was valued at USD 42.20 Billion in 2016. By 2025, the market is expected to reach USD 466.81 Billion while registering a CAGR of 35.3% from 2018 to 2025.
NEW YORK, July 9, 2019 — Within the first quarter of legalization, 5.3 million or 18% of Canadian ages 15 years and older reported using cannabis, according to Statistics Canada. Following legalization, a large number of new users were willing to try cannabis solely because it was legalized and readily accessible. However, a year prior to legalization, only around 14% of Canadians reported using the plant. During the quarter, approximately 646,000 of the users reported trying cannabis for the first time, rising dramatically when compared to 327,000 users a year prior. Overall, the rise year-over-year is largely due to the abundance of male users between the ages of 45 to 64.
Generally, within that age group, adults tend to use cannabis for
medical purposes, largely due to medical conditions associated with
aging. For instance, cases such as chronic pain, Alzheimer’s, and
Parkinson’s are typically associated with the older generation. And
through extensive studies, researchers have discovered that cannabis can
be used to treat these and several other medical conditions.
Furthermore, based on gender, a more significant amount of males used
cannabis when compared to females and it was estimated that 22.3% of
Canadian males used cannabis compared to only 12.7% of females.
Now, while the large increase in users is largely attributable to the
older generation, cannabis is also much more prevalent among the
younger generation. Statistics Canada reported that 29.5% of Canadians
ages 15 to 24 years old used cannabis in the first quarter. Similarly,
approximately 28.7% of Canadians ages 25 to 34-year-olds also used
cannabis during the quarter.
While the adoption of cannabis grew among Canadians, it is important
to remember that the market is still maturing. And despite its
legalization, there are still many legal barriers imposed on the market,
restricting the growth of businesses. Nonetheless, the market is
projected to continually grow throughout the shortcoming years,
developing into a global industry leader. And according to data compiled
by Verified Market Research, the global marijuana market was valued at
USD 42.20 Billion in 2016. By 2025, the market is expected to reach USD
466.81 Billion while registering a CAGR of 35.3% from 2018 to 2025.
Tags: Cannabis, CBD, CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in North Bud Farms Inc | Comments Off on North Bud Farms Inc. $NBUD.ca – Consumer Entry into the #Cannabis Market Spikes Post Legalization $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 2:49 PM on Tuesday, July 2nd, 2019
WHY NORTHBUD FARMS?
Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening this year As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
Infused products sector has become the highest margin segment of the industry
Positioned to be a raw input producer for this space
Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products
In 2018, Eureka recognized revenue of approximately CAD$11.5 million*
net profit margin of 16%* from its California and Colorado operations
Anticipates further growth in revenue due to anticipated changes to retail regulation of adult cannabis use in California.
Justin Braune, CEO of Eureka Vapor, joins Scott to share the
company’s background and why Eureka was an ideal match for North Bud.
Watch until the end to hear Justin’s predictions on Federal
de-regulation in the US.
FULL DISCLOSURE: NORTHBUD is an advertising client of AGORA Internet Relations Corp.
